Although they have different mechanisms of action, both drugs are routinely used in combination with first-line chemotherapy for patients with metastatic colorectal cancer (mCRC) with KRAS wild-type exon 2 tumors [2,3]. Here, KRAS is linked to metastatic colorectal cancer.